PROCEPT BioRobotics Corporation (PRCT)
- Previous Close
52.28 - Open
52.31 - Bid 51.75 x 100
- Ask 51.89 x 100
- Day's Range
51.07 - 52.77 - 52 Week Range
24.83 - 54.79 - Volume
576,341 - Avg. Volume
488,120 - Market Cap (intraday)
2.664B - Beta (5Y Monthly) 1.01
- PE Ratio (TTM)
-- - EPS (TTM)
-2.24 - Earnings Date May 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
58.57
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
www.procept-biorobotics.comRecent News: PRCT
Performance Overview: PRCT
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRCT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRCT
Valuation Measures
Market Cap
2.69B
Enterprise Value
2.51B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
18.14
Price/Book (mrq)
9.57
Enterprise Value/Revenue
18.42
Enterprise Value/EBITDA
-25.58
Financial Highlights
Profitability and Income Statement
Profit Margin
-77.76%
Return on Assets (ttm)
-19.11%
Return on Equity (ttm)
-44.33%
Revenue (ttm)
136.19M
Net Income Avi to Common (ttm)
-105.9M
Diluted EPS (ttm)
-2.24
Balance Sheet and Cash Flow
Total Cash (mrq)
257.22M
Total Debt/Equity (mrq)
28.88%
Levered Free Cash Flow (ttm)
-106.37M